Aldeyra Therapeutics (ALDX) Stock Forecast & Price Target

Aldeyra Therapeutics has demonstrated significant progress with its lead product candidate, Reproxalap, which achieved a successful primary endpoint in clinical trials for dry eye disease, showing a statistically significant improvement over the vehicle treatment. The recent dataset supporting Reproxalap's efficacy could address the concerns raised by the FDA in the April 2025 Complete Response Letter, enhancing the likelihood of regulatory approval. Furthermore, the potential collaboration with AbbVie to commercialize Reproxalap presents a strategic opportunity to compete effectively in the dry eye disease market, particularly against the backdrop of impending generic competition for Restasis.

Aldeyra Therapeutics Inc reported a net loss of $9.9 million, or $0.17 per share, for the first quarter of 2025, indicating ongoing financial challenges. The company faces significant risks, including the potential failure of its developmental candidates to reach expected commercial revenue targets, difficulties in securing necessary capital resources, and the possibility of stalled program development and commercialization efforts. These factors contribute to a negative outlook on the company's financial stability and growth potential in the biotechnology sector.